|Slideshows|May 6, 2016

Eating Disorders in 4 Clinical Reports

Leaders in the field provide specific, effective interventions for these debilitating disorders.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe Now!

Related Content

Tolerance to Stimulant Medications in the Treatment of Children With ADHD

ByJames M. Swanson, PhD,Anthony A. Grace, PhD

November 21st 2025

The Future of ADHD Care: Redefining Adult Diagnosis and Treatment

ByCorina Weir, PhD

November 20th 2025

ADHD and Mild Cognitive Impairment/Early Dementia: A Clinical Reality

ByDavid W. Goodman, MD

November 19th 2025

ADHD: Correcting Careless Myths

ByStephen Mateka, DO

November 18th 2025

Tardive Dyskinesia in Older Adults: Identification and Management in Long-Term Care Settings

ByAmita R. Patel, MD, CMD, MHA, CPE

October 23rd 2025

Latest CME

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Video

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Video

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Video

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Eating Disorders in 4 Clinical Reports

Newsletter

Related Content

Tolerance to Stimulant Medications in the Treatment of Children With ADHD

The Future of ADHD Care: Redefining Adult Diagnosis and Treatment

ADHD and Mild Cognitive Impairment/Early Dementia: A Clinical Reality

ADHD: Correcting Careless Myths

Tardive Dyskinesia in Older Adults: Identification and Management in Long-Term Care Settings

Latest CME

Real Psychiatry 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Optimizing Care for Patients With Tardive Dyskinesia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

The Concept of Mental Illness, and Why the DSM Approach Is Wrong

Okie Tokie Talk: Adolescent Cannabis Use in Oklahoma, the Sooner State

Delay on Cobenfy Alzheimer Disease Psychosis Data Following Phase 3 Study “Irregularities,” New Patients Enrolled

Data Presentation on XPro1595 for Alzheimer Disease With Inflammation at CTAD

Antidepressants Assessed for Reducing Negative Symptoms of Schizophrenia